Bartosz Hudzik/LinkedIn
Feb 11, 2026, 16:08
Bartosz Hudzik: Clinical Trials to Watch in 2026 – A Cardiovascular Lens
Bartosz Hudzik, Editorial Consultant at JACC Case Reports, shared on LinkedIn:
“Clinical trials to watch in 2026 — a cardiovascular lens
Nature Medicine highlights 11 trials poised to shape medicine in 2026. In cardiology, two stand out:
- Ziltivekimab – targeting the IL-6 inflammatory pathway to reduce residual inflammatory risk in atherosclerosis and CKD, moving beyond lipid-only prevention.
- Pelacarsen – a first-in-class antisense therapy for lipoprotein(a), tackling one of the most important genetically driven and previously untreatable CV risk factors.
Both are Phase 3 programs with the potential to redefine precision prevention.
2026 may be the year cardiovascular medicine shifts from risk markers to causal, target-specific therapies.”
More posts featuring Bartosz Hudzik on Hemostasis Today.
-
May 19, 2026, 16:41Selina Marwa: Strengthening Sickle Cell Disease Prevention and Care in Africa
-
May 19, 2026, 16:34Congratulations to the NNHF Project of the Year 2026 Winner
-
May 19, 2026, 16:32Veronica Sanchez: Early Screening Matters in CKM Syndrome
-
May 19, 2026, 16:24Fredrick Chalinga: The Science Behind Recombinant Factor VIIa in Hemophilia A
-
May 19, 2026, 16:15Najmul Hasan Forhad: VWF Concentrates in Modern Hematology and Transfusion Medicine
-
May 19, 2026, 16:10Anirban Sen Gupta: Lyophilized Synthetic Platelets as a Stable Powder for Rapid Hemorrhage Control
-
May 19, 2026, 16:02Stroke Foundation Contributes to National Roundtable on Women’s Cardiovascular Health
-
May 19, 2026, 15:57Explore the Emerging Science Behind Factor XI/XIa Inhibition on the ISTH Academy – ISTH
-
May 19, 2026, 15:55Highlighting Key Achievements and Critical Updates from Iran’s National Blood System – IBTO